Syed Shahab, MD
Internal Medicine · Howell, MINPI 1912940123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,716, 4.5 times the $384 reported in 2019. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$958
- Novo Nordisk$790
- Pfizer$562
- Otsuka America Pharmaceutical, Inc.$401
- Bayer$279
- Amgen$209
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 49 | $958 |
| Novo Nordisk | 50 | $790 |
| Pfizer | 34 | $562 |
| Otsuka America Pharmaceutical, Inc. | 22 | $401 |
| Bayer | 15 | $279 |
| Amgen | 12 | $209 |
| Lilly USA, LLC | 11 | $191 |
| Lundbeck LLC | 8 | $164 |
| E.r. Squibb & Sons, L.L.C. | 7 | $127 |
| Exact Sciences | 5 | $114 |
| Boehringer Ingelheim | 7 | $113 |
| Novartis | 6 | $111 |
| GSK | 6 | $103 |
| Acadia Pharmaceuticals Inc | 4 | $73 |
| Sumitomo Pharma America, Inc. | 3 | $72 |
| Merck | 6 | $71 |
| Abbott | 3 | $63 |
| Astellas Pharma US Inc | 4 | $58 |
| Abiomed | 3 | $55 |
| Johnson & Johnson | 2 | $37 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $30 |
| Philips North America LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $8 |
How this compares
$4,725 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 260 | $194,986 |
| OzempicSemaglutide | 138 | $150,061 |
| FarxigaDapagliflozin Propanediol | 92 | $98,088 |
| XareltoRivaroxaban | 52 | $60,355 |
| JardianceEmpagliflozin | 51 | $52,274 |
| TrulicityDulaglutide | 46 | $47,948 |
| JanuviaSitagliptin Phosphate | 40 | $45,745 |
| MyrbetriqMirabegron | 45 | $27,347 |
| RybelsusSemaglutide | 16 | $26,700 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $18,242 |
| Atorvastatin Calcium | 850 | $10,724 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $7,942 |
| NovologInsulin Aspart | 17 | $6,123 |
| Levothyroxine Sodium | 486 | $5,348 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $562 | $197,651271 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $790 | $182,885171 claims |
| AstraZenecaFarxiga, Symbicort | $958 | $100,882103 claims |
| Johnson & JohnsonXarelto | $37 | $60,35552 claims |
| Boehringer IngelheimJardiance | $113 | $52,27451 claims |
| MerckJanuvia, Dulera | $71 | $50,10052 claims |
| Lilly USA, LLCTrulicity | $191 | $47,94846 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $27,34745 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $103 | $23,15930 claims |
| AbbVieSynthroid | $15 | $2,94048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Howell
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.